Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$3.88+0.06 (+1.57%)
Close on Nov 11, 2026Market cap $767.65MP/E 3.5Yield –
Arbutus Biopharma enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Arbutus Biopharma's enterprise value was $674.20M on Nov 11, 2026, against $752.81M a year earlier. Over the last 5 years it ranged from $83.60M to $911.36M, with a median of $476.21M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $674.20M | -18.7% |
| 2025 | Dec 31, 2025 | $829.60M | +68.7% |
| 2024 | Dec 31, 2024 | $491.67M | +72.5% |
| 2023 | Dec 29, 2023 | $285.06M | +28.9% |
| 2022 | Dec 30, 2022 | $221.10M | -20.2% |
| 2021 | Dec 31, 2021 | $277.03M | +52.1% |
| 2020 | Dec 31, 2020 | $182.10M | +167.9% |
| 2019 | Dec 31, 2019 | $67.96M | -3.5% |
| 2018 | Dec 31, 2018 | $70.44M | -62.9% |
| 2017 | Dec 29, 2017 | $189.83M | – |
| 2016 | Dec 30, 2016 | -$15.32M | -132.8% |
| 2015 | Dec 31, 2015 | $46.74M | -79.6% |
| 2014 | Dec 31, 2014 | $228.81M | +241.6% |
| 2013 | Dec 31, 2013 | $66.99M | +30.8% |
| 2012 | Dec 31, 2012 | $51.23M | +1554.9% |
| 2011 | Dec 30, 2011 | $3.10M | – |
See a number that looks wrong?